Desnick R J, Wang A M
Division of Medical and Molecular Genetics, Mount Sinai School of Medicine, New York, NY 10029.
J Inherit Metab Dis. 1990;13(4):549-59. doi: 10.1007/BF01799512.
The clinical, pathological and biochemical features of a neuroaxonal dystrophy resulting from the deficient activity of lysosomal alpha-N-acetylgalactosaminidase are described. This neurodegenerative disorder was recognized in two brothers who had the typical clinical manifestations and neuropathological lesions observed in patients with Seitelberger disease, the infantile form of neuroaxonal dystrophy. Axonal 'spheroids' were observed histologically in the grey matter, and ultrastructural examination revealed the characteristic formations in dystrophic axons in the myenteric plexus and neocortex. Using a newly synthesized fluorogenic substrate, 4-methylumbelliferyl-alpha-N-acetylgalactosaminide, the markedly deficient activity of alpha-N-acetylgalactosaminidase was demonstrated in the affected brothers while their consanguineous parents had intermediate activities, consistent with the autosomal recessive transmission of this disease. No detectable alpha-N-acetylgalactosaminidase was seen in immunoblots using monospecific rabbit antihuman alpha-N-acetylgalactosaminidase antibodies. Abnormally increased amounts of urinary glycopeptides were observed by high resolution thin layer chromatography. Analytical studies identified four of the accumulating urinary compounds, the blood group A trisaccharide GalNAc alpha 1----3(Fuc alpha 1----2)Gal and three O-linked glycopeptides, GalNAc alpha 1----O-serine and -threonine, NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)GalNAc alpha 1----O-serine and -threonine, and NeuNAc alpha 2----3Gal beta 1----4GlcNAc beta 1----6(NeuNAc alpha 2----3Gal beta 1----3)GalNAc alpha 1----O-serine and -threonine. Of eight unrelated patients diagnosed as having infantile neuroaxonal dystrophy by pathological studies, none had deficient alpha-N-acetylgalactosaminidase activity, emphasizing the biochemical heterogeneity underlying this diagnostic entity. These findings document the first delineation of a metabolic defect in an inherited neuroaxonal dystrophy and suggest that the axonal pathology in this disorder, and perhaps in the other neuroaxonal dystrophies, results from abnormal glycoprotein metabolism involving O-linked glycopeptides.
本文描述了因溶酶体α-N-乙酰半乳糖胺酶活性缺乏导致的神经轴索性营养不良的临床、病理和生化特征。这种神经退行性疾病在两兄弟中被发现,他们具有婴儿型神经轴索性营养不良(即Seitelberger病)患者典型的临床表现和神经病理损伤。组织学检查在灰质中观察到轴突“球体”,超微结构检查揭示了肌间神经丛和新皮质中营养不良轴突的特征性结构。使用新合成的荧光底物4-甲基伞形酮基-α-N-乙酰半乳糖胺,在患病兄弟中证实α-N-乙酰半乳糖胺酶活性明显缺乏,而他们近亲结婚的父母活性处于中间水平,这与该疾病的常染色体隐性遗传一致。使用单特异性兔抗人α-N-乙酰半乳糖胺酶抗体进行免疫印迹时,未检测到α-N-乙酰半乳糖胺酶。通过高分辨率薄层色谱观察到尿糖肽异常增加。分析研究鉴定出四种累积的尿化合物,即血型A三糖GalNAcα1----3(Fucα1----2)Gal和三种O-连接糖肽,GalNAcα1----O-丝氨酸和 - 苏氨酸、NeuNAcα2----3Galβ1----3(NeuNAcα2----6)GalNAcα1----O-丝氨酸和 - 苏氨酸,以及NeuNAcα2----3Galβ1----4GlcNAcβ1----6(NeuNAcα2----3Galβ1----3)GalNAcα1----O-丝氨酸和 - 苏氨酸。在八名经病理研究诊断为婴儿型神经轴索性营养不良的无关患者中,没有一人的α-N-乙酰半乳糖胺酶活性缺乏,这强调了这一诊断实体背后的生化异质性。这些发现首次明确了一种遗传性神经轴索性营养不良中的代谢缺陷,并表明该疾病以及可能其他神经轴索性营养不良中的轴突病理是由涉及O-连接糖肽的异常糖蛋白代谢引起的。